WallStreetZenWallStreetZen

NASDAQ: NBSE
Neubase Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NBSE earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$13.7M
Current Profit Margin
0%

NBSE Return on Equity

Current Company
-103.5%
Current Industry
15.4%
Current Market
-8.4%
NBSE's Return on Equity (-103.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NBSE announces earnings.

NBSE Return on Assets

Current Company
-62.4%
Current Industry
2.2%
NBSE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NBSE Return on Capital Employed

Current Company
-98.24%
Current Industry
17.7%
NBSE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBSE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NBSE$0.00-$12.55M-$13.73MN/AN/A
ATNF$0.00-$22.13M-$19.94MN/AN/A
BPTH$0.00-$15.90M-$16.08MN/AN/A
QLGN$0.00-$11.89M-$13.42M-100.00%N/A
SPRC$797.51k$1.87M$1.42M+108.44%N/A
View Top Biotech Stocks

NBSE earnings dates

Next earnings date
May 13, 2024

Neubase Therapeutics Earnings & Revenue FAQ

What were NBSE's earnings last quarter?

On Invalid Date, Neubase Therapeutics (NASDAQ: NBSE) reported Q3 2023 earnings per share (EPS) of -$0.66, up 86.05% year over year. Total Neubase Therapeutics earnings for the quarter were -$1.82 million. In the same quarter last year, Neubase Therapeutics's earnings per share (EPS) was -$4.73.

If you're new to stock investing, here's how to buy Neubase Therapeutics stock.

What was NBSE's earnings growth in the past year?

As of Q2 2024, Neubase Therapeutics's earnings has grown year over year. Neubase Therapeutics's earnings in the past year totalled -$13.73 million.

What is NBSE's earnings date?

Neubase Therapeutics's earnings date is Invalid Date. Add NBSE to your watchlist to be reminded of NBSE's next earnings announcement.

What was NBSE's revenue last quarter?

On Invalid Date, Neubase Therapeutics (NASDAQ: NBSE) reported Q3 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Neubase Therapeutics's revenue was $0.00.

What was NBSE's revenue growth in the past year?

As of Q2 2024, Neubase Therapeutics's revenue has grown null year over year. Neubase Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.